基于多模态MRI的脑微梗死发病机制及认知功能障碍机制研究

注册号:

Registration number:

ChiCTR2300071649 

最近更新日期:

Date of Last Refreshed on:

2023-07-21 19:49:13 

注册时间:

Date of Registration:

2023-05-22 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于多模态MRI的脑微梗死发病机制及认知功能障碍机制研究

Public title:

Study on the pathogenesis of cerebral microinfarction and the mechanism of cognitive dysfunction based on multimodal MRI

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于多模态MRI的脑微梗死发病机制及认知功能障碍机制研究

Scientific title:

Study on the pathogenesis of cerebral microinfarction and the mechanism of cognitive dysfunction based on multimodal MRI

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

何建风 

研究负责人:

何建风 

Applicant:

He Jianfeng 

Study leader:

He Jianfeng 

申请注册联系人电话:

Applicant telephone:

+86 173 1923 5970

研究负责人电话:

Study leader's
telephone:

+86 173 1923 5970

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

hejf301@163.com

研究负责人电子邮件:

Study leader's E-mail:

hejf301@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

贵州省贵阳市黄河路420号

研究负责人通讯地址:

贵州省贵阳市黄河路420号

Applicant address:

420 Huanghe Road, Huaxi District, Guiyang, Guizhou

Study leader's address:

420 Huanghe Road, Huaxi District, Guiyang, Guizhou

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

贵航贵阳医院

Applicant's institution:

Guihang Guiyang Hospital

研究负责人所在单位:

贵航贵阳医院

Affiliation of the Leader:

Guihang Guiyang Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

202305A

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

贵航贵阳医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Guihang Guiyang Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2023-05-09 00:00:00

伦理委员会联系人:

李兰

Contact Name of the ethic committee:

Li Lan

伦理委员会联系地址:

贵州省贵阳市黄河路420号

Contact Address of the ethic committee:

420 Huanghe Road, Huaxi District, Guiyang, Guizhou

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 851 8811 7467

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

贵航贵阳医院

Primary sponsor:

Guihang Guiyang Hospital

研究实施负责(组长)单位地址:

贵州省贵阳市黄河路420号

Primary sponsor's address:

420 Huanghe Road, Huaxi District, Guiyang, Guizhou

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

贵州

市(区县):

贵阳市

Country:

China

Province:

Guizhou

City:

Guiyang

单位(医院):

贵航贵阳医院

具体地址:

贵阳市黄河路420号

Institution
hospital:

Guihang Guiyang Hospital

Address:

420 Huanghe Road, Huaxi District

经费或物资来源:

自筹

Source(s) of funding:

self-funded

研究疾病:

脑微梗死  

Target disease:

Cerebral microinfarcts

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

1、探索CMI发生率及其危险因素; 2、探查CMI与其他脑小血管病影像标志物的关联; 3、揭示CMI的发病机制; 4、阐释CMI导致认知功能障碍的机制。  

Objectives of Study:

1. To explore the incidence of CMI and its risk factors; 2. To explore the association between CMI and other imaging markers of cerebral small vessel disease; 3. To reveal the pathogenesis of CMI; 4. To elucidate the mechanism by which CMI leads to cognitive dysfunction.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1、图像质量欠佳无法评估分析; 2、其他脑部疾病:如肿瘤、外伤、代谢/中毒、感染等; 3、抑郁或其他精神类疾病。符合上述一项即排除。

Exclusion criteria:

1. Poor image quality that unable to evaluate and analyze; 2. Other brain diseases: such as tumors, trauma, metabolism/poisoning, infections, etc.; 3. Depression or other mental illnesses. If one of the above items is met, it will be exclud.

研究实施时间:

Study execute time:

From 2023-03-30 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-05-22 00:00:00 To 2023-12-31 00:00:00

干预措施:

Interventions:

组别:

Case series

样本量:

288

Group:

Case series

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

贵州 

市(区县):

贵阳 

Country:

China

Province:

Guizhou

City:

Guiyang

单位(医院):

贵航贵阳医院 

单位级别:

三甲 

Institution
hospital:

Guihang Guiyang Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

颅脑MRI参数

指标类型:

主要指标

Outcome:

Brain MRI parameters

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

神经心理学量表评估

指标类型:

次要指标

Outcome:

Neuropsychological assessment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

人口统计学资料

指标类型:

次要指标

Outcome:

Demographic date

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 50 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

none

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

通过数据期刊,以论文形式发表数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Publish date in paper form by journals.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据收集通过病例资料进行记录,后通过电子表格进行整理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Date collection is mainly recorded by medical record form, then date collation is done by electronic form.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-05-22 09:03:09